12:00 AM
Mar 27, 2000
 |  BC Week In Review  |  Clinical News  |  Clinical Status

ISAtx247: Began Phase I testing

Isotechnika Inc. (CDNX:ISA), Edmonton, Alberta
Product: ISAtx247
Business: Autoimmune/Inflammation, Transplant
Therapeutic category: Immune suppression
Target: Calcineurin...

Read the full 68 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >